Symposium
In Vitro Diagnostics (IVD) & Companion Diagnostics (CDx): Guiding Clinical Trials and Patient Treatment through Precision Medicine
Speakers:
Eric Fung (GRAIL), Sharon Pitteri (Stanford), Hua-Fen Liu (Dian Diagnistics), Chris Apfel (Sage Medic), Sean Zhang (Johns Hopkins), Kunbin Qu (Beigene), Mark Girardi (Boston Healthcare), Wen Huang (Vela Diagnostics)
Organizers:
Hui Xu and Wen Huang
Date:
2019-12-10
Time:
8:45-17:00 Pacific Time
Registration fee:
(USD):
Location:
SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date:
(2)PHC former Panasonic Healthcare; Viitai
Registration: http://www.PBSS.org
Registration deadline:2019-12-08
(it will close sooner if the seating cap is reached)
About the Topic
Precision medicine aims to tailor disease prevention and treatment considering differences in individual's genes, environments, and lifestyles. This symposium will review the progress in this field that enable clinicians to quickly, efficiently and accurately predict the most appropriate course of action for a patient and help drug developers to select the right patients for the clinical trials to maximize the probability of clinical success.
Agenda
Section 1: Technologies
Section 2: Applications
Section 3: Commercialization fo IVD Products
8:45 - 9:00 PBSS Welcome Remarks
9:00 - 9:20 Introduction and field overview (Hui Xu, CPO, InterVenn Biosciences)
9:20 - 10:05 Multi-cancer detection of early-stage cancers with simultaneous tissue localization using a plasma cfDNA-based targeted methylation assay (Eric Fung, Senior Group Medical Director, GRAIL)
10:05 - 10:15 major Sponsor's presentation - Crown Bioscience
10:15 - 10:30 Coffee break
10:30 to 11:15 The opportunities and challenges of Metabolomics biomarkers discovery and development in clinical diagnostics (Hua-Fen Liu, CEO, Calibra Diagnostics)
11:15-12:00 Proteomics and Glycoproteomics for Diagnostics (Sharon Pitteri, Associate Professor Of Radiology (Cancer Early Detection-Canary Center), Stanford University)
12:00-1:00 Lunch break
1:00-1:45 Overcoming limitations of next generation sequencing using functional profiling (Chris Apfel, CEO, Sage Medic)
1:45-2:30 Infectious disease applications (Sean Zhang, Associate Professor of Pathology, Johns Hopkins University)
2:30-2:45 Coffee break
2:45-3:15 CDx for clinical trials and drug development (Kunbin Qu, Director of Cancer Genomics, Beigene)
3:15-4:00 Companion Diagnostics in Immuno-Oncology: Global Commercial and Partnership Considerations (Mark Girardi, SVP, Boston Healthcare)
4:00-4:45 A journey to comercial launch of FDA approved IVD products from an IVD Start-up (Wen Huang, CTO & Head of Early Research (Global), Vela Diagnostics)
4:45-5:15 Q&A session and closing remarks
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Online Workshop] Career Transition for Research Scientists
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|